Research Use & Transparency
Statement Purpose and Policy
GLP JOURNEY provides peptides, analogues and related compounds strictly for legitimate scientific and laboratory research purposes only.
All products are clearly labelled as:
For laboratory research use only. Not for human or veterinary use. Not for drug, food, cosmetic, medical or diagnostic application
We do not provide, promote or endorse medical, therapeutic, health, or weight-loss advice. None of our materials are authorised medicines under the Human Medicines Regulations 2012 (UK) or the European Medicines Agency (EMA) frameworks, and they must never be administered to humans or animals.
The only authorised source for genuine GLP JOURNEY products is our official website:
👉 www.glpjourney.co.uk
Any other
website, marketplace, social media account, or individual offering GLP JOURNEY products does so without authorisation. Such listings are fraudulent, and GLP JOURNEY assumes no responsibility for any product or consequence arising from purchases made outside our official platform.
Regulatory Compliance
GLP JOURNEY operates fully within UK and EU legislation governing research chemicals and investigational materials.
Our products are not classed as licensed medicines or clinical therapies. They are supplied solely to qualified researchers, institutions and laboratories engaged in lawful scientific inquiry.
All purchasers accept full responsibility for ensuring compliance with applicable laws, safe handling, and correct disposal under Good Laboratory Practice (GLP) standards.
Industry and Media Context
In recent months, there has been significant media coverage and regulatory discussion surrounding the research-peptide and GLP-1 analogue market in the United Kingdom.
Outlets such as Channel 4, The Guardian, ITV, and Reuters have reported on enhanced MHRA oversight of the wider market, including investigations into what they called unauthorised distribution of unapproved compounds for human use.
These developments illustrate the growing scrutiny of suppliers and the importance of maintaining transparent and compliant operations within the research field.
Separately, Eli Lilly and Company—manufacturer of Mounjaro (Tirzepatide) and patent holder for Retatrutide—has recently announced UK price adjustments aligning domestic costs with international markets.
Healthcare commentators have noted that such changes emphasise the need for responsible sourcing and adherence to regulatory guidance, helping to ensure public safety and avoid misuse of unapproved compounds.
GLP JOURNEY is not affiliated with any pharmaceutical company or vendor mentioned in media reports and does not comment on or condone the practices of other businesses.
We recognise the importance of balanced journalism and fully support ethical, lawful and transparent research within the UK and EU regulatory framework.
Our Commitment
GLP JOURNEY remains dedicated to integrity, compliance and transparency.
We are an independent research supplier — not a medical provider — and we operate with respect for regulatory boundaries, scientific ethics and public safety.
We support innovation through responsible research conducted under approved laboratory conditions.
Final Statement
GLP JOURNEY encourages all customers and researchers to operate transparently, comply with all applicable legislation, and contribute to the advancement of science responsibly and safely.
